A glimpse of the connection between PPARγ and macrophage

Frontiers in Pharmacology

Pharmacology

Yuen Gao¹  Nicole Aaron²  Li Qiang³  Lexiang Yu³ 

[1]Department of Physiology, Michigan State University, East Lansing, MI, United States

[2]Naomi Berrie Diabetes Center, Columbia University, New York, NY, United States

[3]Department of Molecular Pharmacology and Therapeutics, Columbia University, New York, NY, United States

[4]Naomi Berrie Diabetes Center, Columbia University, New York, NY, United States

[5]Department of Pathology and Cell Biology, Columbia University, New York, NY, United States

[6]Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States

关键词: macrophage;    antagonists;    inflammatory diseases;    PPARγ;    anti-inflammatory;   

DOI  :  10.3389/fphar.2023.1254317

 received in 2023-07-10, accepted in 2023-07-31,  发布年份 2023

来源: Frontiers

【 摘 要 】

Nuclear receptors are ligand-regulated transcription factors that regulate vast cellular activities and serve as an important class of drug targets. Among them, peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family and have been extensively studied for their roles in metabolism, differentiation, development, and cancer, among others. Recently, there has been considerable interest in understanding and defining the function of PPARs and their agonists in regulating innate and adaptive immune responses and their pharmacological potential in combating chronic inflammatory diseases. In this review, we focus on emerging evidence for the potential role of PPARγ in macrophage biology, which is the prior innate immune executive in metabolic and tissue homeostasis. We also discuss the role of PPARγ as a regulator of macrophage function in inflammatory diseases. Lastly, we discuss the possible application of PPARγ antagonists in metabolic pathologies.

【 授权许可】

Unknown   
Copyright © 2023 Yu, Gao, Aaron and Qiang.